Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study

被引：0

作者：

Burger, J. A. ^{[1
]}

Barr, P. M. ^{[2
]}

Allan, J. N. ^{[3
]}

Siddiqi, T. ^{[4
]}

Wierda, W. G. ^{[5
]}

Tam, C. S. ^{[6
,7
]}

Moreno, C. ^{[8
]}

Tedeschi, A. ^{[9
]}

Szafer-Glusman, E. ^{[10
]}

Zhou, C. ^{[10
]}

Abbazio, C. ^{[10
]}

Dean, J. P. ^{[10
]}

Szoke, A. ^{[10
]}

Ghia, P. ^{[11
,12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Rochester, Wilmot Canc Inst, Med Ctr, Rochester, MN USA

[3] Weill Cornell Med, New York, NY USA

[4] City Hope Natl Med Ctr, Duarte, CA USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[6] Alfred Hlth, Melbourne, Vic, Australia

[7] Monash Univ, Melbourne, Vic, Australia

[8] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

[9] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[10] AbbVie, South San Francisco, CA USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] IRCCS Osped San Raffaele, Milan, Italy

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V557

引用

页码：87 / 88

页数：2

共 50 条

[1] Fixed-duration ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Wierda, William G.
Tam, Constantine Si Lun
Moreno, Carolina D.
Tedeschi, Alessandra
Szafer-Glusman, Edith
Zhou, Cathy
Abbazio, Chris
Dean, James P.
Szoke, Anita
Ghia, Paolo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Fixed-Duration First-Line Treatment With Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of the Fixed-Duration Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 4 - 5
[3] Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
Ghia, Paolo
Allan, John N.
Siddiqi, Tanya
Kipps, Thomas J.
Jacobs, Ryan
Opat, Stephen
Barr, Paul M.
Tedeschi, Alessandra
Trentin, Livio
Bannerji, Rajat
Jackson, Sharon
Kuss, Byrone
Moreno, Carol
Szafer-Glusman, Edith
Russell, Kristin
Zhou, Cathy
Ninomoto, Joi Suzuki
Dean, James P.
Wierda, William G.
Tam, Constantine Si Lun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Fixed-duration (FD) ibrutinib (I) plus venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.
Wierda, William G.
Barr, Paul M.
Siddiqi, Tanya
Allan, John N.
Kipps, Thomas J.
Trentin, Livio
Jacobs, Ryan
Jackson, Sharon
Tedeschi, Alessandra
Opat, Stephen
Bannerji, Rajat
Kuss, Bryone J.
Moreno, Carol
Croner, Lisa J.
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Dean, James P.
Ghia, Paolo
Tam, Constantine Si Lun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] THE PHASE 2 CAPTIVATE STUDY: PRIMARY ANALYSIS OF A FIXED-DURATION COHORT FOLLOWING FIRST-LINE TREATMENT WITH IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Dela Rosa, Maria
Anderson, Blanche
Ninomoto, Joi
Krigsfeld, Gabe
Wierda, William
Siddiqi, Tanya
ONCOLOGY NURSING FORUM, 2022, 49 (02) : E55 - E56
[6] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Tam, Constantine S.
Siddiqi, Tanya
Allan, John N.
Kipps, Thomas J.
Flinn, Ian W.
Kuss, Bryone J.
Opat, Stephen
Barr, Paul M.
Tedeschi, Alessandra
Jacobs, Ryan
Badoux, Xavier C.
Ghia, Paolo
Sukbuntherng, Juthamas
Salem, Ahmed Hamed
Russell, Kristin
Eckert, Karl
Zhou, Cathy
Ninomoto, Joi
James, Danelle F.
Wierda, William G.
BLOOD, 2019, 134
[7] Outcomes in high-risk subgroups after fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
Wierda, William G.
Jacobs, Ryan
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Tedeschi, Alessandra
Kipps, Thomas J.
O'Brien, Susan Mary
Badoux, Xavier C.
Visentin, Andrea
Lasica, Masa
Carney, Dennis
Camburn, Anna Elinder
Torroba, Javier De la Serna
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Dean, James P.
Ghia, Paolo
Tam, Constantine S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Tam, Constantine S.
Allan, John N.
Siddiqi, Tanya
Kipps, Thomas J.
Jacobs, Ryan
Opat, Stephen
Barr, Paul M.
Tedeschi, Alessandra
Trentin, Livio
Bannerji, Rajat
Jackson, Sharon
Kuss, Bryone J.
Moreno, Carol
Szafer-Glusman, Edith
Russell, Kristin
Zhou, Cathy
Ninomoto, Joi
Dean, James P.
Wierda, William G.
Ghia, Paolo
BLOOD, 2022, 139 (22) : 3278 - 3289
[9] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 14 - 15
[10] Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Wierda, William G.
Jacobs, Ryan
Barr, Paul M.
Allan, John N.
Siddiqi, Tanya
Tedeschi, Alessandra
Kipps, Thomas J.
O'Brien, Susan M.
Badoux, Xavier C.
Visentin, Andrea
Lasica, Masa
Carney, Dennis
Camburn, Anna Elinder
De la Serna, Javier
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Dean, James P.
Ghia, Paolo
Tam, Constantine S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S342 - S342

← 1 2 3 4 5 →